BridgeBio Pharma(BBIO)高管介绍_美股行情_同花顺金融网

来自 : stockpage.10jqka.com.cn/BBIO/m 发布时间：2021-03-25

Frank McCormick，博士，2003年7月以来一直是董事。自1998年以来他一直是加州大学旧金山分校Helen Diller Family 综合癌症中心董事，他目前是加州大学旧金山分校医学院副院长。他是加州大学旧金山分校微生物学和免疫学部门肿瘤和癌症研究所的David A. Wood教授和肿瘤学E. Dixon Heise特聘教授。他从2012年4月到2013年4月担任美国癌症研究协会总裁，这是一个科学组织，使命是通过研究、教育、沟通和协作预防和治疗癌症。他从1992年到1998年是Onyx Pharmaceuticals公司的创始人和首席科学官，一家生物技术公司。从1991年到1992年他担任Chiron公司治疗研究公司副总裁，一家制药公司并从1981年到1990年他担任Cetus公司发现研究副总裁，一家生物技术公司。他是一些最著名的国际癌症的出版物编辑部成员，作为多个癌症研究组织的董事会成员或顾问。他和Dr. Allen Smith是英国伦敦皇家癌症研究基金的一位博士后研究员，和Seymour S. Cohen教授是纽约州立大学斯托尼布鲁克分校研究员。他持有伯明翰大学的生物化学学士学位，英国剑桥大学的生物化学博士学位。

Frank McCormick has served as a member of our board of directors since December 2014. Dr. McCormick has served as the Chairman of Oncology at BridgeBio Pharma, Inc. since April 2019. He has held the position of Director the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, a multidisciplinary research and medical care organization and served as Associate Dean of the University of California, San Francisco School of Medicine from 1997 to 2014. Prior to joining the University of California, San Francisco faculty, Dr. McCormick pursued cancer-related work with several biotechnology firms, including Cetus Corporation as Director of Molecular Biology from 1981 to 1990 and Vice President of Research from 1990 to 1991 and Chiron Corporation as Vice President of Research from 1991 to 1992. In 1992 he founded Onyx Pharmaceuticals Inc. and served as its Chief Scientific Officer until 1996. He also served as a member of the board of directors of Aduro Biotech, Inc., a publicly traded biotechnology company, from 2010 to February 2019. Dr. McCormick received his B.Sc. in biochemistry from the University of Birmingham, and his Ph.D. in biochemistry from the University of Cambridge and held postdoctoral fellowships in the U.S. at the State University of New York at Stony Brook and in London at the Imperial Cancer Research Fund. Dr. McCormick is a Fellow of the Royal Society, an institution dedicated to science, since 1996 a member of the National Academy of Sciences since 2014 and has served as President, from 2012 to 2013 for the American Association for Cancer Research. Since 2013 Dr. McCormick has led the National Cancer Institute s Ras Initiative at the Frederick National Laboratories for Cancer Research overseeing the national effort to develop therapies against Ras-driven cancers. Frank McCormick，博士，2003年7月以来一直是董事。自1998年以来他一直是加州大学旧金山分校Helen Diller Family 综合癌症中心董事，他目前是加州大学旧金山分校医学院副院长。他是加州大学旧金山分校微生物学和免疫学部门肿瘤和癌症研究所的David A. Wood教授和肿瘤学E. Dixon Heise特聘教授。他从2012年4月到2013年4月担任美国癌症研究协会总裁，这是一个科学组织，使命是通过研究、教育、沟通和协作预防和治疗癌症。他从1992年到1998年是Onyx Pharmaceuticals公司的创始人和首席科学官，一家生物技术公司。从1991年到1992年他担任Chiron公司治疗研究公司副总裁，一家制药公司并从1981年到1990年他担任Cetus公司发现研究副总裁，一家生物技术公司。他是一些最著名的国际癌症的出版物编辑部成员，作为多个癌症研究组织的董事会成员或顾问。他和Dr. Allen Smith是英国伦敦皇家癌症研究基金的一位博士后研究员，和Seymour S. Cohen教授是纽约州立大学斯托尼布鲁克分校研究员。他持有伯明翰大学的生物化学学士学位，英国剑桥大学的生物化学博士学位。 Frank McCormick has served as a member of our board of directors since December 2014. Dr. McCormick has served as the Chairman of Oncology at BridgeBio Pharma, Inc. since April 2019. He has held the position of Director the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, a multidisciplinary research and medical care organization and served as Associate Dean of the University of California, San Francisco School of Medicine from 1997 to 2014. Prior to joining the University of California, San Francisco faculty, Dr. McCormick pursued cancer-related work with several biotechnology firms, including Cetus Corporation as Director of Molecular Biology from 1981 to 1990 and Vice President of Research from 1990 to 1991 and Chiron Corporation as Vice President of Research from 1991 to 1992. In 1992 he founded Onyx Pharmaceuticals Inc. and served as its Chief Scientific Officer until 1996. He also served as a member of the board of directors of Aduro Biotech, Inc., a publicly traded biotechnology company, from 2010 to February 2019. Dr. McCormick received his B.Sc. in biochemistry from the University of Birmingham, and his Ph.D. in biochemistry from the University of Cambridge and held postdoctoral fellowships in the U.S. at the State University of New York at Stony Brook and in London at the Imperial Cancer Research Fund. Dr. McCormick is a Fellow of the Royal Society, an institution dedicated to science, since 1996 a member of the National Academy of Sciences since 2014 and has served as President, from 2012 to 2013 for the American Association for Cancer Research. Since 2013 Dr. McCormick has led the National Cancer Institute s Ras Initiative at the Frederick National Laboratories for Cancer Research overseeing the national effort to develop therapies against Ras-driven cancers.